Response of Triple Negative Breast Cancer to Neoadjuvant Chemotherapy: Correlation between Ki-67 Expression and Pathological Response |
Elnemr, Gamal M
(Department of Internal Medicine, Faculty of Medicine, Taif University)
El-Rashidy, Ahmed H (Department of Pathology, Faculty of Medicine, Al-Azhar University (Assuit Branch)) Osman, Ahmed H (Department of Pathology, Faculty of Medicine, Taif University) Issa, Lotfi F (Department of Community Medicine, Faculty of Medicine, Al-Azhar University) Abbas, Osama A (Department of Clinical Oncology, Faculty of Medicine, Ain-Shams University) Al-Zahrani, Abdullah S (Oncology Center, King Abdullah Medical City, Holly Capital) El-Seman, Sheriff M (Oncology Center, King Abdullah Medical City, Holly Capital) Mohammed, Amrallah A (Department of Medical Oncology, Faculty of Medicine, Zagagzig University) Hassan, Abdelghani A (Department of Physiology, Faculty of Medicine, Taif University) |
1 | Masuda H, Baggerly KA, Wang Y, et al (2013). Differential pathologic complete response rates after neoadjuvant chemotherapy among molecular subtypes of triple-negative breast cancer. ASCO Annual Meeting Proc, 1005. |
2 | Mayer IA, Abramson VG, Lehmann BD, et al (2014). New strategies for triple-negative breast cancer-deciphering the heterogeneity. Clinical Cancer Res, 20, 782-90. DOI |
3 | Milde-Langosch K, Karn T, Muller V, et al (2013). Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer. Breast Cancer Res Treatment, 137, 57-67. DOI |
4 | Peddi PF, Ellis MJ, Ma C (2011). Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer, 2012. |
5 | Rocca A, Viale G, Gelber RD, et al (2008). Pathologic complete remission rate after cisplatin-based primary chemotherapy in breast cancer: correlation with p63 expression. Cancer Chemotherapy Pharmacol, 61, 965-71. DOI |
6 | Silver DP, Richardson AL, Eklund AC, et al (2010). Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol, 28, 1145-53. DOI |
7 | Sorlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74. DOI |
8 | Von Minckwitz G, Martin M (2012). Neoadjuvant treatments for triple-negative breast cancer (TNBC). Ann Oncol, 23, 35-9. |
9 | Yerushalmi R, Woods R, Ravdin PM, et al (2010). Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol, 11, 174-83. DOI |
10 | Anders CK, Carey LA (2009). Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clinical Breast Cancer, 9, 73-81. DOI |
11 | Andre F, Zielinski C (2012). Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. Ann Oncology, 23, 46-51. DOI |
12 | Aysola K, Desai A, Welch C, et al (2013). Triple negative breast cancer-an overview. Hereditary Genetics: Current Research, 2013. |
13 | Berrada N, Delaloge S, Andre F (2010). Treatment of triplenegative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? Ann Oncol, 21, 30-5. DOI |
14 | Bidard F-C, Matthieu M-C, Chollet P, et al (2008). p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol, 19, 1261-5. DOI |
15 | Gluz O, Liedtke C, Gottschalk N, et al (2009). Triple-negative breast cancer-current status and future directions. Ann Oncol, 492. |
16 | Burstein HJ, Harris JR, Morrow M (2008). Malignant tumors of the breast. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Lippincott, Williams & Wilkins, 1606-54. |
17 | Edge SB, Byrd DR, Compton CC, et al (2010). AJCC cancer staging manual, Springer New York. |
18 | Gerdes J, Li L, Schlueter C, et al (1991). Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol, 138, 867. |
19 | Inwald E, Klinkhammer-Schalke M, Hofstädter F, et al (2013). Ki-67 is a prognostic parameter in breast cancer patients:results of a large population-based cohort of a cancer registry. Breast Cancer Res Treatment, 139, 539-52. DOI |
20 | Keam B, Im S-A, Lee K-H, et al (2011). Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res, 13, 22. |
21 | Liedtke C, Mazouni C, Hess KR, et al (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol, 26, 1275-81. DOI |
22 | Liu M, Mo QG, Wei CY, et al (2013). Platinum‑based chemotherapy in triple‑negative breast cancer: A meta‑analysis. Oncology letters, 5, 983-91. DOI |
23 | Luporsi E, Andre F, Spyratos F, et al (2012). Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treatment, 132, 895-915. DOI |